FLT3 and acute myeloid leukemia: Gilteritinib, a type I inhibitor targeting AXL, has demonstrated effectiveness as a single therapy in relapsed/refractory FLT3-mutated AML and significantly improved survival compared to salvage chemotherapy [11,12].